Vancomycin in combination with ciprofloxacin exhibited synergy against 7 of 10 strains of Pseudomonas aeruginosa. MICs for the microbial strains used in this study ranged from 0.0325 to 3.0 tig/ml for ciprofloxacin and from 23.5 to >188 ,ug/ml for vancomycin. Combinations of these antibiotics, tested in a checkerboard pattern, gave fractional inhibitory concentrations of 0.5 or less for 7 of the 10 strains tested.
Infections caused by Pseudomonas aeruginosa are complicated by the fact that antibiotic resistance is both widespread and rapidly acquired. The newest class of antibiotics for therapy against these infections are the fluoroquinolones, typified by ciprofloxacin. Their mechanism of action is believed to be inhibition of DNA gyrase, preventing both replication and repair of DNA, affecting both actively growing (replication) and more slowly growing cells (repair processes). Fluoroquinolone activity, which is blocked by chloramphenicol, dinitrophenol, and amino acid starvation, requires both new protein synthesis and a functioning electron transport system (3, 4, 6, 18) .
Fluoroquinolone resistance involves either mutations affecting the DNA gyrase (7) or reduced permeability of the bacterial outer membranes. In Escherichia coli, a reduction in porins and diminished expression of ompF have been observed in permeability mutants. Reduced concentrations of OmpF in the envelope correlate with decreased fluoroquinolone penetration (8, 9) . The inner membrane plays an integral role in the accumulation of these antibiotics (2) . Studies of everted inner membrane vesicles from resistant E. coli reveal energy-dependent uptake of quinolones. This process is carrier mediated and driven by proton motive force, suggesting an active efflux mechanism for fluoroquinolones.
Organisms in which resistance to fluoroquinolones is most commonly encountered include P. aeruginosa and methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis. In 1984, virtually 100% of P. aenrginosa isolates in the United States, Europe, and Japan were susceptible to <1 ,ug of ciprofloxacin per ml. Today, some institutions report that 25% of their P. aeruginosa isolates are resistant to all the fluoroquinolones (13) . Little research has been done on fluoroquinolone resistance mechanisms in P. aeruginosa even though ciprofloxacin is a widely used agent in the treatment of P. aeruginosa infections (14, 15) . Interest in the mechanism of lipopolysaccharide (LPS) secretion by P. aeruginosa led us to investigate the effects of vancomycin and ciprofloxacin on this organism.
Ciprofloxacin Determinations of synergy were made with the standard checkerboard technique by the method of Lorian (11) . Bacterial inocula were obtained from Mueller-Hinton broth cultures incubated overnight on a rotary shaker (150 rpm) at 37°C. The bacterial density was adjusted by using a Gilford Response II spectrophotometer (Ciba-Corning Diagnostics), and tubes were inoculated to a final concentration of 5.0 x 105 cells per ml. The MIC, the lowest antibiotic concentration that exhibited no visible turbidity, was determined after incubation at 24 and 48 h at 37°C. Synergy was defined according to the standard described by Lorian (11) , where synergy is a fractional inhibitory concentration (FIC) index of c0.5.
The ciprofloxacin MICs (24 h) for the P. aeruginosa test strains ranged from 0.0375 to 0.75 p,g/ml, and at 48 h they ranged from 0.325 to 3.0 p,g/ml. Vancomycin inhibition was tested across the range from 0 to 188 p,g/ml. The MIC of vancomycin at 24 h was >188 p,g/ml for 5 of the 10 strains and at 48 h for 7 of the 10 strains ( Table 1 ). The FIC indices calculated from the checkerboard analysis for each strain showed synergy between these two antibiotics for 8 of the 10 test strains ( Table 2 ). In some cases, the FIC index could only be estimated from the highest concentration of vancomycin used (188 ,ug/ml) because an MIC was not observed for this antibiotic. The MIC decreases ranged from 0 to 16-fold and were highest after 48 h of incubation (Table 3) .
For the most part, the concentration of vancomycin required to give the maximum MIC reduction for ciprofloxacin was less than 47 ±g/ml. A vancomycin concentration of 47 pLg/ml is within the peak level in serum achieved after the administration of therapeutic doses to humans (12) . In vitro testing of fluoroquinolones in combination with other antimicrobial agents has been tried previously, with mixed success. The results of the studies are consistent.
Fluoroquinolones in combination with many 1-lactams or aminoglycosides usually have additive or indifferent effects; occasionally they are synergistic but rarely antagonistic (1, 5) . Vancomycin used in combination with ciprofloxacin against gram-positive microorganisms had an antagonistic effect (14, 16, 18 ). An in vivo study of a combination of ciprofloxacin and vancomycin for treatment of bacteremias showed a 70% improvement for treatment of gram-negative infections and no antagonism between the antibiotics. Two cases of P. aeruginosa infections showed no improvement (16) . Some ciprofloxacin-resistant mutants of P. aeruginosa show altered LPS patterns. Their 0 antigens are truncated, as shown by the loss of the ladder pattern upon electrophoresis, suggesting the involvement of LPS in the expression of ciprofloxacin resistance (10) . Vancomycin interferes with glycosylation, translocation reactions of peptidoglycan, and 0-antigen biosynthesis. Peptidoglycan and 0-antigen biosynthesis utilize similar translocation processes, via the C55 isoprenoid carrier. Vancomycin and 0-antigen biosynthesis share a common point of action, the C55 bacterioprenol lipid carrier. It is tempting to speculate that the loss of the ladder pattern, an indication of an energy-driven efflux mechanism for the antibiotic, and the synergy observed between vancomycin and ciprofloxacin suggest that 0-antigen biosynthesis and ciprofloxacin efflux share a common pathway. If they do share a common pathway, then efflux of the fluoroquinolones would exhibit direct competition with 0-antigen biosynthesis. Resistant strains would have shorter 0-antigen side chains on their LPS. This has in fact been observed in P. aeruginosa (10) .
These results suggest that the addition of vancomycin to a course of fluoroquinolone antibiotic therapy may in some cases increase the effectiveness of this antimicrobial agent against P. aeruginosa. Since vancomycin also inhibits a pathway that is essential to cell functioning (0-antigen and peptidoglycan biosynthesis), development of resistance to this antimicrobial combination may be an infrequent event.
